Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C12H22O35S8 |
Molecular Weight | 982.802 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)OC[C@H]1O[C@@](COS(O)(=O)=O)(O[C@H]2O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1OS(O)(=O)=O
InChI
InChIKey=WEPNHBQBLCNOBB-UGDNZRGBSA-N
InChI=1S/C12H22O35S8/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36)/t4-,5-,6-,7-,8+,9-,10+,11-,12+/m1/s1
Molecular Formula | C12H22O35S8 |
Molecular Weight | 982.802 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Sucrosofate (sucrose octasulfate) is a class of organic compounds known as disaccharide sulfates carrying one or more sulfate group on a sugar unit. It is used to encapsulate some anticancer drugs in liposomes allowing for highly active formulations against solid tumors and immunotargeting to cancer-overexpressing cell surface receptors. ONIVYDE (liposomal irinotecan) for intravenous use encapsulates an aqueous space containing irinotecan in a gelated or precipitated state as the sucrose octasulfate salt was initially approved by FDA in 1996 for treatment of pancreatic cancer. Sucrose octasulfate (SOS), a chemical analogue of heparin, has been demonstrated to activate fibroblast growth factors signalling pathways and SOS-mediated dimerization of FGF1 was observed. SOS can suppress thrombin generation in plasma that suggests a potential for oversulfated disaccharides in controlling heparin cofactor II -regulated thrombin generation.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Structure and stability of an acidic fibroblast growth factor from Notophthalmus viridescens. | 2002 Nov 29 |
|
Binding of sucrose octasulphate to the C-type lectin-like domain of the recombinant natural killer cell receptor NKR-P1A observed by NMR spectroscopy. | 2002 Nov 4 |
|
Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. | 2002 Oct |
|
Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness. | 2005 Feb |
|
Therapeutic paint of cidofovir/sucralfate gel combination topically administered by spraying for treatment of orf virus infections. | 2009 Jun |
|
Topical use of sucralfate in epithelial wound healing: clinical evidences and molecular mechanisms of action. | 2010 Jan |
|
Development of a highly stable and targetable nanoliposomal formulation of topotecan. | 2010 Jan 4 |
Sample Use Guides
Recommended dose of ONIVYDE is 70 mg/m^2 intravenous infusion over 90 minutes every two weeks. Recommended starting dose of ONIVYDE in patients homozygous for UGT1A1*28 is 50 mg/m^2 every two weeks.There is no recommended dose of ONIVYDE for patients with serum bilirubin above the upper limit of normal.
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Oct 22 05:29:08 UTC 2019
by
admin
on
Tue Oct 22 05:29:08 UTC 2019
|
Record UNII |
P7V86EYZ5L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C802
Created by
admin on Tue Oct 22 05:29:08 UTC 2019 , Edited by admin on Tue Oct 22 05:29:08 UTC 2019
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB10667MIG
Created by
admin on Tue Oct 22 05:29:08 UTC 2019 , Edited by admin on Tue Oct 22 05:29:08 UTC 2019
|
PRIMARY | |||
|
CHEMBL1235872
Created by
admin on Tue Oct 22 05:29:08 UTC 2019 , Edited by admin on Tue Oct 22 05:29:08 UTC 2019
|
PRIMARY | |||
|
6618
Created by
admin on Tue Oct 22 05:29:08 UTC 2019 , Edited by admin on Tue Oct 22 05:29:08 UTC 2019
|
PRIMARY | |||
|
C053081
Created by
admin on Tue Oct 22 05:29:08 UTC 2019 , Edited by admin on Tue Oct 22 05:29:08 UTC 2019
|
PRIMARY | |||
|
C152444
Created by
admin on Tue Oct 22 05:29:08 UTC 2019 , Edited by admin on Tue Oct 22 05:29:08 UTC 2019
|
PRIMARY | |||
|
444237
Created by
admin on Tue Oct 22 05:29:08 UTC 2019 , Edited by admin on Tue Oct 22 05:29:08 UTC 2019
|
PRIMARY | |||
|
57680-56-5
Created by
admin on Tue Oct 22 05:29:08 UTC 2019 , Edited by admin on Tue Oct 22 05:29:08 UTC 2019
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |